There’s Time to Consider Fertility Preservation Options
Women with breast cancer who choose fertility preservation have treatment outcomes similar to women who don’t undergo fertility preservation.
Progress Against Cancer
Women with breast cancer who choose fertility preservation have treatment outcomes similar to women who don’t undergo fertility preservation.
Researchers aim to minimize disease relapses by targeting multiple proteins.
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented challenges on the health care system and threatened our hopes of an end to the...
Patient expenses for cancer care exceed $21 billion in 2019, the FDA introduces stringent requirements for breast implants and more news of the week from Cancer Today.
Liver cancer is the second most common cause of cancer-related deaths worldwide. In 2021, it is estimated that more than 42,000 people will be diagnosed with the disease and approximately 30,000 will die because...
On Wednesday, the American Association for Cancer Research (AACR) released its annual Cancer Progress Report. Now in its 11th year, the report details advances in the cancer research continuum, provides a comprehensive review of anticancer drugs, diagnostic tools, and devices approved by the U.S. Food and Drug Administration in the past year, shines a...
study shows the cost of drugs that manage cancer-related symptoms adds up, and more news of the week from Cancer Today magazine.
As the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved got underway on Wednesday, a trio of keynote speakers provided different perspectives on this critical field of research. The...
Researchers create breast cancer prediction models tailored for Asian Americans.
MRI can be a cost-effective way to screen for breast cancer, and more news of the week from Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More